Amgen and Daiichi Sankyo make deal for biosimilars in Japan

Home/Pharma News | Posted 05/08/2016 post-comment0 Post your comment

US-based biologicals specialist Amgen and Japan-based Daiichi Sankyo announced on 13 July 2016 that they had made an exclusive agreement to commercialize nine biosimilars in Japan.

Shaking hands V13D29

The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab.

Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialization in Japan, while Amgen will have a limited right to co-promote the products.

Amgen will retain all additional distribution and commercialization rights for the biosimilar programmes outside of Japan.

Daiichi Sankyo also made an agreement with US-based biosimilars specialist Coherus BioSciences back in May 2012 for the development and commercialization of biosimilars of etanercept and rituximab in certain Asian countries including Japan [1].

This latest deal marks another move by Daiichi Sankyo’s to diversify away from proprietary medicines. The company has already made major moves into generics, with the purchase of Indian generics company Ranbaxy for US$5.4 billion in 2010 [2].

Related article
Positive phase III results for Amgen’s trastuzumab biosimilar

1. GaBI Online - Generics and Biosimilars Initiative. Daiichi Sankyo and Coherus Biosciences make biosimilars deal []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Aug 5]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Ranbaxy to transfer R & D and focus on generics []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Aug 5]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: Amgen

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010